Discuss MannKind Corp.
MannKind Corp.
WKN: A2DMZL / Symbol: MNKD / Name: MannKind / Aktie / Biotechnologie & medizinische Forschung / Small Cap /
5,34 €
-0,67 %
Buy MannKind Corp.
MannKind Co. (NASDAQ: MNKD) had its price target raised by analysts at Cantor Fitzgerald from $6.50 to $7.50. They now have an "overweight" rating on the stock.
Ratings data for MNKD provided by MarketBeat
MannKind Co. (NASDAQ: MNKD) is now covered by analysts at Wedbush. They set an "outperform" rating on the stock.
Ratings data for MNKD provided by MarketBeat
MannKind Co. (NASDAQ: MNKD) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.50 price target on the stock.
Ratings data for MNKD provided by MarketBeat
MannKind Co. (NASDAQ: MNKD) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $6.50 price target on the stock.
Ratings data for MNKD provided by MarketBeat
MannKind Co. (NASDAQ: MNKD) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $10.00 price target on the stock.
Ratings data for MNKD provided by MarketBeat
MannKind Co. (NASDAQ: MNKD) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $6.50 price target on the stock.
Ratings data for MNKD provided by MarketBeat
MannKind Co. (NASDAQ: MNKD) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $6.50 price target on the stock.
Ratings data for MNKD provided by MarketBeat
MannKind Co. (NASDAQ: MNKD) is now covered by analysts at Rodman & Renshaw. They set a "buy" rating and a $8.00 price target on the stock.
Ratings data for MNKD provided by MarketBeat
Neueste Beiträge
Roth_Mkm in MGP Ingredients Inc. diskutieren